Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023

Jennifer DeCuir; Diya Surie; Yuwei Zhu; Manjusha Gaglani; Adit A. Ginde; David J. Douin; H. Keipp Talbot; Jonathan D. Casey; Nicholas M. Mohr; Tresa McNeal; Shekhar Ghamande; Kevin W. Gibbs; D. Clark Files; David N. Hager; Minh Phan; Matthew E. Prekker; Michelle N. Gong; Amira Mohamed; Nicholas J. Johnson; Jay S. Steingrub; Ithan D. Peltan; Samuel M. Brown; Emily T. Martin; Arnold S. Monto; Akram Khan; William S. Bender; Abhijit Duggal; Jennifer G. Wilson; Nida Qadir; Steven Y. Chang; Christopher Mallow; Jennie H. Kwon; Matthew C. Exline; Adam S. Lauring; Nathan I. Shapiro; Cristie Columbus; Robert Gottlieb; Ivana A. Vaughn; Mayur Ramesh; Lois E. Lamerato; Basmah Safdar; Natasha Halasa; James D. Chappell; Carlos G. Grijalva; Adrienne Baughman; Kelsey N. Womack; Jillian P. Rhoads; Kimberly W. Hart; Sydney A. Swan; Nathaniel Lewis; Meredith L. McMorrow; Wesley H. Self

doi:10.15585/mmwr.mm7217a3

Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023

Jennifer DeCuir, Diya Surie, Yuwei Zhu, Manjusha Gaglani, Adit A. Ginde, David J. Douin, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Tresa McNeal, Shekhar Ghamande, Kevin W. Gibbs, D. Clark Files, David N. Hager, Minh Phan, Matthew E. Prekker, Michelle N. Gong, Amira Mohamed, Nicholas J. Johnson, Jay S. SteingrubIthan D. Peltan, Samuel M. Brown, Emily T. Martin, Arnold S. Monto, Akram Khan, William S. Bender, Abhijit Duggal, Jennifer G. Wilson, Nida Qadir, Steven Y. Chang, Christopher Mallow, Jennie H. Kwon, Matthew C. Exline, Adam S. Lauring, Nathan I. Shapiro, Cristie Columbus, Robert Gottlieb, Ivana A. Vaughn, Mayur Ramesh, Lois E. Lamerato, Basmah Safdar, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Adrienne Baughman, Kelsey N. Womack, Jillian P. Rhoads, Kimberly W. Hart, Sydney A. Swan, Nathaniel Lewis, Meredith L. McMorrow, Wesley H. Self

Pulmonary and Critical Care Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths in the United States, with approximately 75% of deaths occurring among adults aged ≥65 years (1). Data on the durability of protection provided by monovalent mRNA COVID-19 vaccination against critical outcomes of COVID-19 are limited beyond the Omicron BA.1 lineage period (December 26, 2021-March 26, 2022). In this case-control analysis, the effectiveness of 2-4 monovalent mRNA COVID-19 vaccine doses was evaluated against COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death among immunocompetent adults aged ≥18 years during February 1, 2022-January 31, 2023. Vaccine effectiveness (VE) against IMV and in-hospital death was 62% among adults aged ≥18 years and 69% among those aged ≥65 years. When stratified by time since last dose, VE was 76% at 7-179 days, 54% at 180-364 days, and 56% at ≥365 days. Monovalent mRNA COVID-19 vaccination provided substantial, durable protection against IMV and in-hospital death among adults during the Omicron variant period. All adults should remain up to date with recommended COVID-19 vaccination to prevent critical COVID-19-associated outcomes.

Original language	English (US)
Pages (from-to)	463-468
Number of pages	6
Journal	Morbidity and Mortality Weekly Report
Volume	72
Issue number	17
DOIs	https://doi.org/10.15585/mmwr.mm7217a3
State	Published - Apr 28 2023

ASJC Scopus subject areas

Epidemiology
Health(social science)
Health, Toxicology and Mutagenesis
Health Information Management

Access to Document

10.15585/mmwr.mm7217a3

Fingerprint

Dive into the research topics of 'Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023'. Together they form a unique fingerprint.

Cite this

DeCuir, J., Surie, D., Zhu, Y., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., McNeal, T., Ghamande, S., Gibbs, K. W., Files, D. C., Hager, D. N., Phan, M., Prekker, M. E., Gong, M. N., Mohamed, A., Johnson, N. J., ... Self, W. H. (2023). Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023. Morbidity and Mortality Weekly Report, 72(17), 463-468. https://doi.org/10.15585/mmwr.mm7217a3

Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023. / DeCuir, Jennifer; Surie, Diya; Zhu, Yuwei et al.
In: Morbidity and Mortality Weekly Report, Vol. 72, No. 17, 28.04.2023, p. 463-468.

Research output: Contribution to journal › Article › peer-review

DeCuir, J, Surie, D, Zhu, Y, Gaglani, M, Ginde, AA, Douin, DJ, Talbot, HK, Casey, JD, Mohr, NM, McNeal, T, Ghamande, S, Gibbs, KW, Files, DC, Hager, DN, Phan, M, Prekker, ME, Gong, MN, Mohamed, A, Johnson, NJ, Steingrub, JS, Peltan, ID, Brown, SM, Martin, ET, Monto, AS, Khan, A, Bender, WS, Duggal, A, Wilson, JG, Qadir, N, Chang, SY, Mallow, C, Kwon, JH, Exline, MC, Lauring, AS, Shapiro, NI, Columbus, C, Gottlieb, R, Vaughn, IA, Ramesh, M, Lamerato, LE, Safdar, B, Halasa, N, Chappell, JD, Grijalva, CG, Baughman, A, Womack, KN, Rhoads, JP, Hart, KW, Swan, SA, Lewis, N, McMorrow, ML & Self, WH 2023, 'Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023', Morbidity and Mortality Weekly Report, vol. 72, no. 17, pp. 463-468. https://doi.org/10.15585/mmwr.mm7217a3

DeCuir J, Surie D, Zhu Y, Gaglani M, Ginde AA, Douin DJ et al. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023. Morbidity and Mortality Weekly Report. 2023 Apr 28;72(17):463-468. doi: 10.15585/mmwr.mm7217a3

DeCuir, Jennifer ; Surie, Diya ; Zhu, Yuwei et al. / Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023. In: Morbidity and Mortality Weekly Report. 2023 ; Vol. 72, No. 17. pp. 463-468.

@article{62c1f471e3a9434a9971f7ffc8981361,

title = "Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023",

abstract = "As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths in the United States, with approximately 75% of deaths occurring among adults aged ≥65 years (1). Data on the durability of protection provided by monovalent mRNA COVID-19 vaccination against critical outcomes of COVID-19 are limited beyond the Omicron BA.1 lineage period (December 26, 2021-March 26, 2022). In this case-control analysis, the effectiveness of 2-4 monovalent mRNA COVID-19 vaccine doses was evaluated against COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death among immunocompetent adults aged ≥18 years during February 1, 2022-January 31, 2023. Vaccine effectiveness (VE) against IMV and in-hospital death was 62% among adults aged ≥18 years and 69% among those aged ≥65 years. When stratified by time since last dose, VE was 76% at 7-179 days, 54% at 180-364 days, and 56% at ≥365 days. Monovalent mRNA COVID-19 vaccination provided substantial, durable protection against IMV and in-hospital death among adults during the Omicron variant period. All adults should remain up to date with recommended COVID-19 vaccination to prevent critical COVID-19-associated outcomes.",

author = "Jennifer DeCuir and Diya Surie and Yuwei Zhu and Manjusha Gaglani and Ginde, {Adit A.} and Douin, {David J.} and Talbot, {H. Keipp} and Casey, {Jonathan D.} and Mohr, {Nicholas M.} and Tresa McNeal and Shekhar Ghamande and Gibbs, {Kevin W.} and Files, {D. Clark} and Hager, {David N.} and Minh Phan and Prekker, {Matthew E.} and Gong, {Michelle N.} and Amira Mohamed and Johnson, {Nicholas J.} and Steingrub, {Jay S.} and Peltan, {Ithan D.} and Brown, {Samuel M.} and Martin, {Emily T.} and Monto, {Arnold S.} and Akram Khan and Bender, {William S.} and Abhijit Duggal and Wilson, {Jennifer G.} and Nida Qadir and Chang, {Steven Y.} and Christopher Mallow and Kwon, {Jennie H.} and Exline, {Matthew C.} and Lauring, {Adam S.} and Shapiro, {Nathan I.} and Cristie Columbus and Robert Gottlieb and Vaughn, {Ivana A.} and Mayur Ramesh and Lamerato, {Lois E.} and Basmah Safdar and Natasha Halasa and Chappell, {James D.} and Grijalva, {Carlos G.} and Adrienne Baughman and Womack, {Kelsey N.} and Rhoads, {Jillian P.} and Hart, {Kimberly W.} and Swan, {Sydney A.} and Nathaniel Lewis and McMorrow, {Meredith L.} and Self, {Wesley H.}",

year = "2023",

month = apr,

day = "28",

doi = "10.15585/mmwr.mm7217a3",

language = "English (US)",

volume = "72",

pages = "463--468",

journal = "Morbidity and Mortality Weekly Report",

issn = "0149-2195",

publisher = "Department of Health and Human Services",

number = "17",

}

TY - JOUR

T1 - Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023

AU - DeCuir, Jennifer

AU - Surie, Diya

AU - Zhu, Yuwei

AU - Gaglani, Manjusha

AU - Ginde, Adit A.

AU - Douin, David J.

AU - Talbot, H. Keipp

AU - Casey, Jonathan D.

AU - Mohr, Nicholas M.

AU - McNeal, Tresa

AU - Ghamande, Shekhar

AU - Gibbs, Kevin W.

AU - Files, D. Clark

AU - Hager, David N.

AU - Phan, Minh

AU - Prekker, Matthew E.

AU - Gong, Michelle N.

AU - Mohamed, Amira

AU - Johnson, Nicholas J.

AU - Steingrub, Jay S.

AU - Peltan, Ithan D.

AU - Brown, Samuel M.

AU - Martin, Emily T.

AU - Monto, Arnold S.

AU - Khan, Akram

AU - Bender, William S.

AU - Duggal, Abhijit

AU - Wilson, Jennifer G.

AU - Qadir, Nida

AU - Chang, Steven Y.

AU - Mallow, Christopher

AU - Kwon, Jennie H.

AU - Exline, Matthew C.

AU - Lauring, Adam S.

AU - Shapiro, Nathan I.

AU - Columbus, Cristie

AU - Gottlieb, Robert

AU - Vaughn, Ivana A.

AU - Ramesh, Mayur

AU - Lamerato, Lois E.

AU - Safdar, Basmah

AU - Halasa, Natasha

AU - Chappell, James D.

AU - Grijalva, Carlos G.

AU - Baughman, Adrienne

AU - Womack, Kelsey N.

AU - Rhoads, Jillian P.

AU - Hart, Kimberly W.

AU - Swan, Sydney A.

AU - Lewis, Nathaniel

AU - McMorrow, Meredith L.

AU - Self, Wesley H.

PY - 2023/4/28

Y1 - 2023/4/28

N2 - As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths in the United States, with approximately 75% of deaths occurring among adults aged ≥65 years (1). Data on the durability of protection provided by monovalent mRNA COVID-19 vaccination against critical outcomes of COVID-19 are limited beyond the Omicron BA.1 lineage period (December 26, 2021-March 26, 2022). In this case-control analysis, the effectiveness of 2-4 monovalent mRNA COVID-19 vaccine doses was evaluated against COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death among immunocompetent adults aged ≥18 years during February 1, 2022-January 31, 2023. Vaccine effectiveness (VE) against IMV and in-hospital death was 62% among adults aged ≥18 years and 69% among those aged ≥65 years. When stratified by time since last dose, VE was 76% at 7-179 days, 54% at 180-364 days, and 56% at ≥365 days. Monovalent mRNA COVID-19 vaccination provided substantial, durable protection against IMV and in-hospital death among adults during the Omicron variant period. All adults should remain up to date with recommended COVID-19 vaccination to prevent critical COVID-19-associated outcomes.

AB - As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths in the United States, with approximately 75% of deaths occurring among adults aged ≥65 years (1). Data on the durability of protection provided by monovalent mRNA COVID-19 vaccination against critical outcomes of COVID-19 are limited beyond the Omicron BA.1 lineage period (December 26, 2021-March 26, 2022). In this case-control analysis, the effectiveness of 2-4 monovalent mRNA COVID-19 vaccine doses was evaluated against COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death among immunocompetent adults aged ≥18 years during February 1, 2022-January 31, 2023. Vaccine effectiveness (VE) against IMV and in-hospital death was 62% among adults aged ≥18 years and 69% among those aged ≥65 years. When stratified by time since last dose, VE was 76% at 7-179 days, 54% at 180-364 days, and 56% at ≥365 days. Monovalent mRNA COVID-19 vaccination provided substantial, durable protection against IMV and in-hospital death among adults during the Omicron variant period. All adults should remain up to date with recommended COVID-19 vaccination to prevent critical COVID-19-associated outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85159244954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159244954&partnerID=8YFLogxK

U2 - 10.15585/mmwr.mm7217a3

DO - 10.15585/mmwr.mm7217a3

M3 - Article

C2 - 37104244

AN - SCOPUS:85159244954

SN - 0149-2195

VL - 72

SP - 463

EP - 468

JO - Morbidity and Mortality Weekly Report

JF - Morbidity and Mortality Weekly Report

IS - 17

ER -

Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this